As it makes its transition from FIPCo to FIPNet, Big Pharma seeks to populate its vendor network with trustworthy suppliers and partners to reduce costs while feeding its discovery pipeline. Your Combi-Chem efforts are producing a lot of viable compounds but how are you going to meaningfully and cost-effectively test them to find the right drug candidates? The Algos team has played keys roles in successful pharmaceutical pain discovery programs and understands the challenges you and your company are facing. We know the preclinical landscape and can help you cost effectively navigate it. Most importantly, we have the expertise to measure your candidates against the right tests to de-risk your decision making as much as possible.
As the Lead Discovery Scientist for your biotech’s pain program, you have limited resources with which to fully characterize your IP and make it attractive to potential investors. If pain is one of your targets then we can help. Algos has taken multiple products through the pre-clinical stage to clinical development and can help you prepare the pharmacological profile investors are looking for.
You have a delivery system and a drug, and need to understand how well they work together in a variety of pain paradigms. Do you trust the project and the product’s potential revenue to an academic lab? Or do you choose a partner who has the expertise and wherewithal to expedite the required research? At Algos, we have investigated hundreds of combinations of drugs and delivery systems, and can provide the hands on expertise and guidance that will help you reach your goals. Contact us today. Your proof of concept is only a phone call or click away.
